| Literature DB >> 29743906 |
Marcin Tkaczyk1,2, Daria Tomczyk3, Anna Jander1, Sebastian Góreczny4, Tomasz Moszura4, Paweł Dryżek4, Wojciech Krajewski5, Ewa Głowacka6, Agnieszka Wosiak7.
Abstract
INTRODUCTION: Diagnosis of contrast induced-nephropathy (CIN) by a classic renal biomarker such as creatinine concentration can be delayed because of various factors that can influence this marker. Changes in new biomarkers such as neutrophil-gelatinase associated lipocalin (NGAL) and cystatin C are postulated to be more sensitive for recognizing patients prone to CIN-acute kidney injury (AKI). AIM: To investigate the role of NGAL and cystatin C as early biomarkers in the diagnosis of kidney injury after cardiac catheterisation.Entities:
Keywords: cardiac catheterization; children; contrast-induced acute kidney injury
Year: 2018 PMID: 29743906 PMCID: PMC5939547 DOI: 10.5114/aic.2018.74357
Source DB: PubMed Journal: Postepy Kardiol Interwencyjnej ISSN: 1734-9338 Impact factor: 1.426
Figure 1Clinical description of congenital cardiac malformations in the study group
HLHS – hypoplastic left heart syndrome, TGA – translocation of great arteries, combined malformations without HLHS, other: tetralogy of Fallot, persistent arterial duct, aortopulmonary window.
Clinical and basic biochemical characteristics of the study group
| Parameter | Median and interquartile range or number of patients |
|---|---|
| Age [years] | 4.5 (2.0–8.0) |
| Male/female ratio | 35/15 |
| Cyanotic/non-cyanotic malformation, | 32/18 |
| Malformations with normal/disturbed renal parenchymal flow, | 27/23 |
| Estimated glomerular filtration rate [ml/min/1.73 m2 BSA] | 123.04 (109.86–139.04) |
| Haemoglobin concentration [g/l] | 15 (13.1–16.7) |
| Diagnostic/diagnostic + intervention, | 18/32 |
| Duration of the catheterisation [min] | 50 (38–80) |
| Total dose of the contrast [ml/kg] | 2.82 (1.48–5.49) |
| Total radiation dose [mGy]/time [min] | 166.95 (68.00–230.00)/13.27 (7.31–20.09) |
| RAA blockade before procedure, | 14/36 |
| Proportion of children with diuretic administration before procedure, | 26/24 |
| Heart function by ejection fraction (EF) (%) | 62 (57–71) |
Figure 2Changes in eGFR calculated by modified Schwartz Formula in the observation period (0–2–6–24–48 h)
Changes in serum creatinine, cystatin C, NGAL, eGFR by Schwartz and Filler and selected clinical values in the observation period. Values presented as median and 25–75 interquartile range
| Parameter | Period | Significance (Friedman ANOVA) | ||||
|---|---|---|---|---|---|---|
| Initial | 2 | 6 | 24 | 48 | ||
| Serum creatinine [mg/dl] | 0.3 (0.3–0.4) | 0.4 (0.3–0.4) | 0.4 (0.3–0.4) | 0.4 (0.3–0.4) | 0.3 (0.3–0.4) | < 0.001 |
| eGFR by Schwartz [ml/min/1.73 m2 BSA] | 123.04 (109.86–139.04) | 114.78 (103.25–136.29) | 111.17 (103.25–130.10) | 112.54 (103.25–131.13) | 120.80 (108.76–138.36) | < 0.001 |
| Serum cystatin C [ng/ml] | 644.95 (566.9–746.4) | 650.85 (552.5–743.6) | 646.5 (538.8–781.8) | 636.45 (523.4–750.0) | 634.05 (485.5–746.4) | 0.938 |
| eGFR by Filler [ml/min/1.73 m2 BSA] | 64.11 (54.41–74.10) | 63.46 (54.66–76.27) | 63.93 (51.65–78.45) | 65.07 (54.11–81.05) | 65.35 (54.41–88.19) | 0.938 |
| Serum NGAL [ng/ml] | 20.42 (21.80–49.60) | 21.49 (22.70–51.10) | 30.70 (23.00–57.50) | 19.08 (18.10–42.20) | 21.67 (14.30–40.00) | < 0.001 |
| Mean arterial pressure [mm Hg] | 73.33 (65.00–77.67) | 69.83 (63.67–78.00) | 71.33 (63.67–78.67) | 73.67 (65.17–80.50) | 77.33 (68.67–81.67) | 0.480 |
| Systolic blood pressure [mm Hg] | 101 (90–110) | 100 (91–108) | 99 (89–108) | 105 (91–112) | 104 (95–116) | 0.366 |
| Urine output [ml/kg/h] | X | 4.55 (3.46–8.28) | 5.38 (3.75–8.88) | 1.99 (1.39–2.78) | 2.91 (2.01–5.05) | 0.161 |
eGFR – estimated glomerular filtration rate, NGAL – neutrophil gelatinase.
Figure 3Changes in serum NGAL concentration in the observation period
Figure 4Serum NGAL concentration in children with normal and diminished renal blood flow
Comparison of serum NGAL and cystatin C in children with AKI by RIFLE and non-AKI patients
| Patients | Parameter | Period | Significance (Friedman ANOVA) | ||||
|---|---|---|---|---|---|---|---|
| Initial | 2 | 6 | 24 | 48 | |||
| Non AKI | Serum cystatin C [ng/ml] | 675 (587.1–795) | 647.7 (551.75–747.3) | 684.6 (545.7–795.6) | 677.75 (522.25–802.57) | 636.6 (504.5–781.4) | 0.956 |
| AKI | Serum cystatin C [ng/ml] | 604.3 (535.25–683.25) | 635.55 (553.7–719.92) | 575.7 (443.1–656.55) | 598.05 (514.57–720.07) | 613.8 (464.2–670.97) | 0.845 |
| Significance by Mann-Whitney test | NS | NS | NS | NS | NS | ||
| Non AKI | Serum NGAL [ng/ml] | 28.3 (19.7–49.6) | 40.2 (26.15–55.6) | 41.7 (21.8–57.5) | 28.7 (18.85–42.72) | 22 (11.7–38.9) | < 0.001 |
| AKI | Serum NGAL [ng/ml] | 27.4 (23.95–40.15) | 29.65 (22.52–46.45) | 40.45 (22.8–56) | 28.9 (17.9–39.45) | 26 (15.05–38.3) | < 0.001 |
| Significance by Mann-Whitney test | NS | NS | NS | NS | NS | ||